Lilly Partners with Rigel on RIPK1 Inhibitors
By Michelle Liu
Pharma Deals Review: Vol 2021 Issue 3 (Table of Contents)
Published: 2 Mar-2021
DOI: 10.3833/pdr.v2021.i3.2595 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Joining the RIPK1 inhibitor race, Eli Lilly has agreed to partner with Rigel Pharmaceuticals to co-develop and commercialise the latter’s R552 for all indications including auto immune and inflammatory diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS